Subcutaneous vs intravenous trastuzumab for patients with ERBB2-positive early breast cancer: final analysis of the HannaH Phase 3 randomized clinical trial. JAMA Oncol 2019; 5:e190339.

Published: 18th July 2019

Authors: Jackisch C, Stroyakovskiy D, Pivot X, Ahn JS, Melichar B, Chen SC et al.

Conclusion

The subcutaneous route was non inferior to the intravenous route for trastuzumab in this study that included 596 women: six-year event-free survival hazard ratio 0.98, 95 per cent confidence interval 0.74 to 1.29; and overall survival (84 per cent in both groups) hazard ratio 0.94, 0.61 to 1.45.

Pubmed Link

Your comments

0 Comments